Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
169 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Rank Status Study
21 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib
22 Recruiting Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Pioglitazone Hydrochloride;   Drug: Tyrosine Kinase Inhibitor (TKI)
23 Recruiting Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib
24 Recruiting A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: ponatinib 30 mg QD;   Drug: ponatinib 15 mg QD;   Drug: nilotinib 400 mg BID
25 Recruiting Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: P1101
26 Recruiting Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Imatinib;   Drug: Dasatinib
27 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
28 Recruiting Allogeneic SCT for CML, TKI Failure After TKI Failure
Condition: Chronic Myeloid Leukemia
29 Recruiting Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia;   Chronic Myeloid Leukemia;   Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Drug: Nilotinib
30 Recruiting Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Chronic Phase;   Adults
Intervention: Drug: Ponatinib
31 Recruiting A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib
Condition: Chronic Myeloid Leukemia
Intervention: Procedure: Stem Cell and Mutational Assay
32 Recruiting Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Condition: Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
33 Not yet recruiting Preparatory Work to Assess Adherence to Oral Chemotherapy
Condition: Chronic Myeloid Leukemia
34 Not yet recruiting Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
35 Recruiting A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Condition: Chronic Myeloid Leukemia
Interventions: Drug: 600mg/day of Imatinib;   Drug: 400mg/day of Imatinib
36 Recruiting Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib (Tasigna ®), capsules of 150 mg;   Drug: Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)
37 Not yet recruiting 2nd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First Unsuccessful Treatment Discontinuation in CML
Condition: Chronic Myeloid Leukemia
Interventions: Other: TKI discontinuation;   Drug: nilotinib
38 Recruiting Radotinib as 3rd or Later Line Therapy in CP-CML
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Radotinib
39 Recruiting An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Imatinib;   Drug: Nilotinib
40 Recruiting Allogeneic Stem Cell Transplantation for Children With CML
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Drug: ATG;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Biological: bone marrow or peripheral blood stem cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.